A number of other research analysts have also commented on ALXN. Zacks Investment Research lowered Alexion Pharmaceuticals from a buy rating to a hold rating in a report on Wednesday, November 1st. Royal Bank Of Canada upped their target price on Alexion Pharmaceuticals to $166.00 in a research note on Tuesday, October 24th. Piper Jaffray Companies restated an overweight rating and issued a $170.00 target price on shares of Alexion Pharmaceuticals in a research note on Monday, October 23rd. Stifel Nicolaus cut their target price on Alexion Pharmaceuticals from $165.00 to $159.00 and set a buy rating for the company in a research note on Tuesday, October 24th. Finally, SunTrust Banks, Inc. reiterated a buy rating and set a $165.00 price objective on shares of Alexion Pharmaceuticals in a research note on Friday, July 14th. Six research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and two have given a strong buy rating to the company. Alexion Pharmaceuticals presently has a consensus rating of Buy and a consensus price target of $154.01.
Shares of Alexion Pharmaceuticals (ALXN) traded down $0.45 on Friday, hitting $107.60. The stock had a trading volume of 1,671,680 shares, compared to its average volume of 2,294,205. The firm has a market cap of $23,940.00, a P/E ratio of 22.10, a price-to-earnings-growth ratio of 1.18 and a beta of 1.22. Alexion Pharmaceuticals has a one year low of $96.18 and a one year high of $149.34. The company has a quick ratio of 2.51, a current ratio of 2.96 and a debt-to-equity ratio of 0.35.
Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.44 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.32 by $0.12. The firm had revenue of $859.00 million during the quarter, compared to analysts’ expectations of $864.34 million. Alexion Pharmaceuticals had a return on equity of 12.55% and a net margin of 14.57%. The company’s revenue was up 7.5% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.23 earnings per share. equities analysts predict that Alexion Pharmaceuticals will post 4.81 earnings per share for the current year.
ILLEGAL ACTIVITY WARNING: This story was published by BBNS and is the property of of BBNS. If you are accessing this story on another site, it was copied illegally and republished in violation of international trademark and copyright law. The original version of this story can be viewed at https://baseballnewssource.com/markets/alexion-pharmaceuticals-inc-alxn-cut-to-c-at-thestreet/1776058.html.
In other news, EVP Julie O’neill sold 4,375 shares of Alexion Pharmaceuticals stock in a transaction that occurred on Tuesday, September 5th. The stock was sold at an average price of $145.44, for a total transaction of $636,300.00. Following the completion of the transaction, the executive vice president now directly owns 26,092 shares in the company, valued at approximately $3,794,820.48. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Ann M. Veneman sold 835 shares of Alexion Pharmaceuticals stock in a transaction that occurred on Tuesday, September 5th. The stock was sold at an average price of $145.81, for a total value of $121,751.35. Following the transaction, the director now owns 5,480 shares of the company’s stock, valued at $799,038.80. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 16,490 shares of company stock valued at $2,337,251. Corporate insiders own 4.35% of the company’s stock.
Hedge funds and other institutional investors have recently modified their holdings of the company. BlackRock Inc. boosted its stake in Alexion Pharmaceuticals by 7.0% in the 2nd quarter. BlackRock Inc. now owns 19,926,265 shares of the biopharmaceutical company’s stock valued at $2,424,428,000 after purchasing an additional 1,298,185 shares during the period. Vanguard Group Inc. boosted its stake in Alexion Pharmaceuticals by 2.2% in the 2nd quarter. Vanguard Group Inc. now owns 14,785,831 shares of the biopharmaceutical company’s stock valued at $1,798,992,000 after purchasing an additional 318,375 shares during the period. State Street Corp boosted its stake in Alexion Pharmaceuticals by 5.0% in the 2nd quarter. State Street Corp now owns 11,860,647 shares of the biopharmaceutical company’s stock valued at $1,443,099,000 after purchasing an additional 561,962 shares during the period. Ameriprise Financial Inc. boosted its stake in Alexion Pharmaceuticals by 3.5% in the 3rd quarter. Ameriprise Financial Inc. now owns 6,390,301 shares of the biopharmaceutical company’s stock valued at $896,491,000 after purchasing an additional 215,005 shares during the period. Finally, Jennison Associates LLC boosted its stake in Alexion Pharmaceuticals by 720.0% in the 3rd quarter. Jennison Associates LLC now owns 5,332,636 shares of the biopharmaceutical company’s stock valued at $748,116,000 after purchasing an additional 4,682,336 shares during the period. Institutional investors own 95.80% of the company’s stock.
Alexion Pharmaceuticals Company Profile
Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).
Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with our FREE daily email newsletter.